On Invalid Date, Marker Therapeutics (NASDAQ: MRKR) reported Q4 2023 earnings per share (EPS) of -$0.32, up 28.89% year over year. Total Marker Therapeutics earnings for the quarter were -$2.80 million. In the same quarter last year, Marker Therapeutics's earnings per share (EPS) was -$0.45.
As of Q1 2024, Marker Therapeutics's earnings has grown year over year. Marker Therapeutics's earnings in the past year totalled -$8.24 million.
What is MRKR's earnings date?
Marker Therapeutics's earnings date is Invalid Date. Add MRKR to your watchlist to be reminded of MRKR's next earnings announcement.
What was MRKR's revenue last quarter?
On Invalid Date, Marker Therapeutics (NASDAQ: MRKR) reported Q4 2023 revenue of $1.06 million up 39.17% year over year. In the same quarter last year, Marker Therapeutics's revenue was $759.14 thousand.
What was MRKR's revenue growth in the past year?
As of Q1 2024, Marker Therapeutics's revenue has grown -5.76% year over year. This is 171.37 percentage points lower than the US Biotechnology industry revenue growth rate of 165.61%. Marker Therapeutics's revenue in the past year totalled $3.31 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.